WO1994026903A2 - Human influenza virus peptides binding hla-i molecule - Google Patents

Human influenza virus peptides binding hla-i molecule Download PDF

Info

Publication number
WO1994026903A2
WO1994026903A2 PCT/NL1994/000114 NL9400114W WO9426903A2 WO 1994026903 A2 WO1994026903 A2 WO 1994026903A2 NL 9400114 W NL9400114 W NL 9400114W WO 9426903 A2 WO9426903 A2 WO 9426903A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
human
influenza virus
residues
peptide according
Prior art date
Application number
PCT/NL1994/000114
Other languages
French (fr)
Other versions
WO1994026903A3 (en
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Original Assignee
Rijksuniversiteit Leiden
Seed Capital Investments (Sci) B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rijksuniversiteit Leiden, Seed Capital Investments (Sci) B.V. filed Critical Rijksuniversiteit Leiden
Priority to AU68585/94A priority Critical patent/AU6858594A/en
Publication of WO1994026903A2 publication Critical patent/WO1994026903A2/en
Publication of WO1994026903A3 publication Critical patent/WO1994026903A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the invention is concerned with novel peptides derived from a protein of the Human Influenza Virus, and their use in or for: 1) the induction of primary influenza-specific T cells that can be used for therapeutic treatment, in particular the induction of HLA class I-restricted CD8 + cytotoxic T cells (CTL) , and 2) pharmaceutical compositions for a prophylactic or therapeutic treatment of human individuals . All against diseases in which the influenza virus is playing a role.
  • CTL cytotoxic T cells
  • Influenza an acute respiratory illness, is known to afflict humans since ancient times. The sudden appearance of epidemics of respiratory diseases persisting for a few weeks and equally sudden disappearance are characteristic. Epidemics vary in severity but usually cause mortality in the elderly. The virus has killed untold millions throughout the centuries and it has also altered the course of history. The severity of the disease accelerated the search for the causative agent. In 1933 the influenza virus was then first isolated from humans [ref 1] . The influenza virus belongs to the group of myxoviruses .
  • Influenza viruses are divided into types A, B and C based on the antigenic differences between their nucleoprotein (NP) and matrix (M; also called membrane) protein antigens. Influenza A viruses are further subdivided into subtypes and the revised nomenclature system includes the host of origin, geographical origin, strain number and year of isolation. Influenza A virus is the most common variety of influenza causing viruses, and is responsible for the pandemics. Influenza B is usually associated with smaller and less virulent outbreaks. The C virus is found only rarely. The structures of influenza viruses of types A, B, and C are similar.
  • hemagglutin (HA) and neuraminidase (NA) glycoproteins are attached by short sequences of hydrophobic amino acids to a lipid envelope derived from the plasma membrane of the host cell. Within the lipid envelope lies the M protein, which is believed to be structural in function. Within the matrix shell are eight single-stranded RNA molecules of negative sense associated with the NP and three large proteins (PB1, PB2 and PA) responsible for RNA replication and transcription. At least three virus-coded nonstructural proteins (NS1, NS2 and M2) are found in infected cells but their functions are unknown [ref 2] . The influenza virus-coded proteins and their major characteristics are shown in Table 1.
  • Ml or M 3000 Major virion component surrounds the core, involved in assembly and budding
  • NP 1000 Internal protein associated with RNA & polymerase proteins, helical arrangement
  • PB1/PB2/PA 30-60 Internal proteins associated with RNA transcriptase activity HA 500 Surface glycoprotein trimer responsible for attachment of virus to cells
  • the ⁇ P is one of the type-specific antigens of influenza viruses that distinguishes among the influenza type A, B, and C viruses.
  • the influenza B and C ⁇ P proteins are larger (560-565 amino acids) than those of type A (498 amino acids) .
  • the ⁇ P is a multifunctional protein having a structural role in forming the ⁇ P complex and a role in transcription and replication.
  • the ⁇ P protein may play a role in determining species specificity. Monoclonal antibodies to the ⁇ P do not provide passive protection and immunization with this protein induces very limited resistance to infection.
  • the ⁇ P protein is a major antigen recognized by cytotoxic lymphocytes (CTL) and several of the epitopes recognized by the CTL are conserved in human influenza A viruses [ref 4, 5] .
  • CTL cytotoxic lymphocytes
  • the Ml protein which is 252 amino acids long, is a virion structural protein that is intimately associated with the lipid bilayer in such a manner that it is in close proximity to both glycoproteins and to the R ⁇ P complex [ref 2, 6] .
  • Ml is encoded in an essentially complete transcript of segment 7. It is believed to be a multifunctional protein also having a role in the downregulation of the activity of the virion-associated transcriptase and is located in the nucleus, cytoplasm and plasma membrane in infected cells [ref 7, 8] . Passively transferred monoclonal antibodies to this protein do not confer resistance to infection [ref 9] .
  • Antigenic drift involves minor antigenic changes in the HA and NA proteins, while antigenic shift involves major antigenic changes in these molecules.
  • Antigenic drift occurs in types A, B, and C virus hemagglutinins but is most pronounced in human influenza A strains.
  • Antigenic drift in the HA occurs by point mutations in the gene, leading to an accumulation of amino acid sequence changes that alter the antigenic sites such that they are no longer recognized by the host's immune system.
  • Antigenic drift also occurs in the NA of influenza viruses and has been correlated with differences in amino acid sequences [ref 11] .
  • the frequency of isolation of NA variants is similar to that for the HA, and sequence analysis shows single amino acid substitutions in the molecule [ref 12] .
  • the humoral immune response in humans is extremely heterogeneous and the limited antibody repertoire against the influenza virus surface antigens in children and young adults probably permits selection of variants with changes in a single epitope [ref 13] .
  • influenza viruses There is no evidence of persistent or latent infection with influenza viruses .
  • the virus is maintained in humans by direct person-to-person spread during acute infection. Immunologic factors clearly influence the size of an epidemic. Immunity is type-specific .
  • Influenza virus is unique among respiratory viruses in being a cause of excess mortality. Influenza A has caused excess mortality 21 times since 1934. Although morbidity with influenza A virus is concentrated in people less than 20 years of age, the highest rates of excess mortality occur in persons over 65 years of age [ref 14] . Mortality due to influenza is not confined to the bedridden since up to 50% of all deaths occurred in people who were chronically ill but medically stable and functioning independently [ref 15] . The average yearly rate of death due to influenza A virus infection is 1 per 2200 adults 65 years or older [ref 16] .
  • the level of memory class I-restricted CTL present at the time of infection correlated with an enhanced clearance of virus from the respiratory tract [ref 18] .
  • Oligopeptides with amino acid sequences similar to those of the ⁇ -terminus of the HA2 polypeptide have antiviral activity against influenza A virus in vitro [ref 19] .
  • the oligopeptides probably act by interfering with the function of the N-terminus of the HA2 polypeptide.
  • Inactivated influenza A and B virus vaccines are licensed for parenteral administration in humans.
  • the vaccines currently in use are designated whole-virus (WV) vaccines or split-product (SP) virus vaccine.
  • WV vaccines contain intact, formalin- treated virus while the SP vaccines contain purified formalin- treated virus disrupted with chemicals that solubilize the lipid-containing viral envelope.
  • Experimental vaccines contain the isolated HA and NA surface proteins. Satisfactory serological responses were achieved in children and adults with doses of vaccine that caused minimal clinical reactions. Local or systemic allergic reactions occur approximately once in every 3900 vaccinations [ref 20] . Intradermal administration offers no advantage over parenteral administration [ref 21] .
  • influenza A and B viruses consistently induces resistance to illness and, to a lesser extent, infection with influenza A and B virus [ref 22, 23] .
  • Efficacy ranges from 60 to 80%, the higher value being obtained following challenge with homologous virus.
  • Vaccine is effective in the elderly who are at high risk for morbidity and mortality, but the level of efficacy is often less than seen in young adults [ref 15, 24] . It is suggested that the immunity is of short duration.
  • Inactivated vaccines stimulate HLA-testricted CTL in adults but their ability to stimulate CTL in unprimed individuals has not been evaluated [ref 25] .
  • inactivated WV and SP vaccines stimulate a poor CTL response in unprimed mice .
  • influenza A viruses do not differ in mutation rate from other RNA viruses, mutation occurs sufficiently often to provide an ample source for the selection of naturally occurring variants.
  • An important part of the resistance to influenza A virus is mediated by the development of an immune response to HA and NA. These glycoproteins are conserved to a much lesser extent compared to the NP and M proteins.
  • This invention is specifically concerned with the detection of class I binding T cell epitopes of the highly conserved M protein of the influenza virus, which can be recognized by CTL. CTL are of crucial importance in the resistance against virus infections [ref 26, 27] .
  • CTL specific for viruses recognize short viral or tumor protein-derived peptides of about 8-11 amino acids in length, that are presented in the antigen binding groove of major histocompatibility complex (MHC) class I molecules [ref 28, 29] .
  • MHC major histocompatibility complex
  • An object of the present invention is therefore to provide synthetic peptides of the influenza M protein for prevention, prophylaxis, therapy and treatment of influenza utilizing these synthetic peptides and pharmaceutical compositions containing the synthetic peptides.
  • Another object of the invention is t to provide a method of prophylactic or therapeutic treatment of influenza or other Human Influenza Virus-related diseases.
  • a further object of the present invention is to provide pharmaceutical compositions which can be used for prevention, prophylaxis, therapy and treatment of influenza or other Human Influenza Virus-related diseases .
  • This invention provides a peptide comprising an amino acid sequence derived from a human influenza virus protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex (MHC) Class I molecule.
  • MHC Major Histocompatibility Complex
  • the present invention also provides specific peptides derived from the amino acid sequence of the human influenza M protein which, because of their capability to bind to HLA molecules, such as e.g. the * HLA-A2.1, HLA-A1, HLA- 3.2, HLA-All.2 or HLA-A24 protein, are candidate peptides to be included in human vaccines that can induce protective or therapeutic T cell responses against human influenza virus .
  • the novel peptides of the present invention are useful in pharmaceutical compositions, as screening tools and in the prevention, prophylaxis, therapy and treatment of influenza or other human influenza virus-induced diseases or other conditions which would benefit from inhibition of influenza virus infection.
  • said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.
  • this invention provides a peptide comprising an amino acid sequence derived from human influenza M protein, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:
  • This invention further provides a pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to the invention, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
  • a pharmaceutical composition contains a peptide according to the invention which is able to induce a T cell response effective against human influenza virus, in particular a HLA class I- restricted CD8 + cytotoxic T cell response.
  • this invention provides a method of prophylactic or therapeutic treatment of influenza or any other human influenza virus-related disease with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a peptide according to the invention, more specifically an immunogenic form of a peptide according to the invention which is able to induce a T cell response effective against human influenza virus, in particular a HLA class I-restricted CD8 + cytotoxic T cell response.
  • the invention provides a peptide as ⁇ efined herein for prophylactically or therapeutically inducing in a human individual a HLA class I-restricted CD8 + cytotoxic T cell response effective against human influenza virus .
  • the invention covers the use of a peptide as defined herein for preparing a pharmaceutical composition for prophylactically or therapeutically inducing in a human individual a HLA class I- restricted CD8 + cytotoxic T cell response effective against human influenza virus .
  • the invention also provides a process of inducing a human influenza virus-specific cytotoxic T lymphocyte response in a T- lymphocyte culture, comprising the steps of loading antigen- presenting cells which carry empty MHC Class I molecules with a peptide as defined herein, culturing T-lymphocytes in the presence of the peptide-loaded antigen-presenting cells under specific cytotoxic T-lymphocyte response-inducing conditions, and, optionally, isolating a human influenza virus-specific cytotoxic T lymphocyte from the resulting culture and culturing said isolated cytotoxic T-lymphocyte .
  • the invention provides a human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide as defined herein, and also provides a pharmaceutical composition containing a prophylactically or therapeutically effective amount of a human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide as defined herein, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
  • the invention also provides a method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a human influenza virus-specific cytotoxic T lympho- cyte reactive to a peptide as defined herein.
  • the invention covers the use of a peptide as defined herein in a diagnostic test or assay to detect human influenza virus- specific T cells or antibodies.
  • the invention is directed to peptides comprising an amino acid sequence derived from a human influenza virus protein, in particular the human influenza M protein, wherein said amino acid sequence has the ability to bind to a human MHC class I molecule, preferably a human HLA-A2.1 class I molecule. More specifically, such peptides comprise the following amino acid sequences derived from the noted regions of the human influenza virus (See Table 2; the amino acids are identified by the one- letter code of amino acids) . Table 2: Influenza matrix peptides identified as peptides binding to HLA-A2.1
  • Polypeptides that are homologs of the peptides specifically include those having amino acid sequences which are at least about 40% conserved in relation to the amino acid sequence set forth in Table 2, preferentially at least about 60% conserved, and more preferentially at least about 75% conserved.
  • Peptides according to the invention include any variation in the amino acid sequence, whether by conservative amino acid substitution, deletion, or other process, provided that the polypeptides bind to the HLA molecule in question.
  • the fragments of the peptides may be small peptides with sequences of as little as five or more amino acids, said sequences being those disclosed in Table 2 when said polypeptides bind to the HLA-A2.1 molecule.
  • Polypeptides larger than peptides ⁇ os . 1-15 are especially included within the scope of the present invention when said polypeptides induce a human influenza M protein specific CTL response in appropriate individuals (e.g. HLA-A2.1 positive individuals) and include a (partial) amino acid sequence as set forth in Table 2, or conservative substitutions thereof.
  • Such polypeptides may have a length up to about 30 amino acids, preferably up to about 27 amino acids. Most preferably, however, the peptides have a length of from 9 to 12, more preferably 9 to 11 amino acids.
  • This invention includes the use of polypeptides ⁇ os. 1-15 generated by every means, whether genetic engineering, peptide synthesis with solid phase techniques or others.
  • the peptides may have various chemical modifications made at the terminal ends and still be within the scope of the present invention. Also other chemical modifications are possible, particularly cyclic and dimeric configurations.
  • derivatives intends to cover all such modified peptides.
  • polypeptides of the present invention find utility for the treatment or prevention of diseases involving the human influenza virus .
  • the peptides are administered in an immunogenic form. Since the peptides are relatively short, this may necessitate conjugation with a immunogenicity conferring carrier material such as lipids or others or the use of adjuvants .
  • polypeptides of this invention will, of course, vary with the group of patients (age, sex, weight, etcetera), the nature of the severity or the condition to be treated, the particular polypeptide of this invention and its route of administration. Any suitable route of administration may be employed to achieve an effective dosage of a polypeptide identified by this invention, as well as any dosage form well known in the art of pharmacy.
  • the polypeptides may also be administered by controlled release means and/or other delivery devices, such as, in particular, interferons and T cell activating agents like interleukin-2 etc.
  • the peptides of this invention may also be useful for other purposes, such as diagnostic use. For example, they may be used to check whether a vaccination with a peptide according to tne present invention has been successful. This may be done in vitro by testing whether the peptide is able to activate T cells of the vaccinated person. They may be used also in diagnostic tests or assays for the detection of human influenza virus- specific antibodies.
  • T2 the antigen processing defective cell line 174.CEM T2 (T2) .
  • This cell line expresses the human MHC class I HLA-A2.1 and HLA-B5 alleles of which only the HLA-A2.1 molecules are expressed as partly empty and unstable molecules that can be stabilized on the cell surface with exogenous addition of peptides binding to the peptide presenting groove of these molecules [ref 32] . If incubation with a peptide results in an increased expression of the HLA- A2.1 on the surface of T2, this implies that the peptide binds to the groove of this MHC class I molecule and is therefore a candidate target antigen for recognition by CTL.
  • the T2 cell line a gift from Dr. P. Cresswell (Dept . of Immunology, Yale University, New Haven, CT) , was cultured in Iscove's modified Dulbecco's medium (IMDM) (Biochrom KG, Seromed Berlin, Germany) with 2mM glutamine, 100 IU/ml penicillin, 100 ⁇ g/ml kanamycin and 10% fetal calf serum (FCS, Hyclone Laboratories Inc. Logan, Utah, USA) . The T2 cells were washed twice in serum free culture medium.
  • IMDM Iscove's modified Dulbecco's medium
  • FITC-labelled F(ab') 2 fragments of goat anti-mouse IgG (Tago Inc Burlinger, CA, USA: 4350) in a dilution of 1:40 was added as the second antibody and incubated for another 30 min at 4°C.
  • the cells were washed once and fluorescence was measured at 488 nanometer on a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) .
  • F.R. mean fluorescence experimental sample / mean fluorescence background.
  • the 77 peptides synthesized and tested are shown in Table 2 (15 high-scoring and binding influenza matrix peptides) , Table 3 (20 high-scoring but non-binding influenza matrix peptides), Table 4 (24 low-scoring, non-binding influenza matrix peptides) and Table 5 (18 non-binding control influenza matrix peptides) .
  • the result of the binding analyses of the 15 binding peptides is given in Table 6.
  • Binding of peptides is shown as mean fluorescence level of HLA-A2.1 expression in the presence of said peptides divided by the mean fluorescence level of HLA- A2.1 expression without the presence of said peptides. Binding of a peptide is regarded as positive when a value of 1.5 is reached.
  • T a b le 3 The non-binding influenza matrix peptides with a high score. The number of the first amino acid is shown. The peptides are ranked according to their computer score .
  • Table 4 The Influenza matrix peptides with a low score. The number of the first amino acid is shown. The peptides are ranked according to their computer score.
  • Table 5 The Influenza matrix peptides used as a control group The number of the first amino acid is shown. The peptides are ranked according to their seq. no.
  • SEQ ID NO:2 SEQUENCE TYPE: amino acid
  • Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States . Am. J. Public Health 1986; 76: 761-765.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A peptide comprising an amino acid sequence derived from a human influenza virus protein, such as the human influenza M protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of a human influenza virus-related disease, or in a diagnostic test or assay.

Description

HUMAN INFLUENZA VIRUS PEPTIDES BINDING HLA-I MOLECULE
Field of the invention
The invention is concerned with novel peptides derived from a protein of the Human Influenza Virus, and their use in or for: 1) the induction of primary influenza-specific T cells that can be used for therapeutic treatment, in particular the induction of HLA class I-restricted CD8+ cytotoxic T cells (CTL) , and 2) pharmaceutical compositions for a prophylactic or therapeutic treatment of human individuals . All against diseases in which the influenza virus is playing a role.
Background of the invention
Influenza, an acute respiratory illness, is known to afflict humans since ancient times. The sudden appearance of epidemics of respiratory diseases persisting for a few weeks and equally sudden disappearance are characteristic. Epidemics vary in severity but usually cause mortality in the elderly. The virus has killed untold millions throughout the centuries and it has also altered the course of history. The severity of the disease accelerated the search for the causative agent. In 1933 the influenza virus was then first isolated from humans [ref 1] . The influenza virus belongs to the group of myxoviruses .
Influenza viruses are divided into types A, B and C based on the antigenic differences between their nucleoprotein (NP) and matrix (M; also called membrane) protein antigens. Influenza A viruses are further subdivided into subtypes and the revised nomenclature system includes the host of origin, geographical origin, strain number and year of isolation. Influenza A virus is the most common variety of influenza causing viruses, and is responsible for the pandemics. Influenza B is usually associated with smaller and less virulent outbreaks. The C virus is found only rarely. The structures of influenza viruses of types A, B, and C are similar. The hemagglutin (HA) and neuraminidase (NA) glycoproteins are attached by short sequences of hydrophobic amino acids to a lipid envelope derived from the plasma membrane of the host cell. Within the lipid envelope lies the M protein, which is believed to be structural in function. Within the matrix shell are eight single-stranded RNA molecules of negative sense associated with the NP and three large proteins (PB1, PB2 and PA) responsible for RNA replication and transcription. At least three virus-coded nonstructural proteins (NS1, NS2 and M2) are found in infected cells but their functions are unknown [ref 2] . The influenza virus-coded proteins and their major characteristics are shown in Table 1.
Table 1: Influenza virus-coded proteins
Designation occurrence* Characteristics
Ml or M 3000 Major virion component, surrounds the core, involved in assembly and budding
MM22 2200--6600 Involved in assembly and budding
NP 1000 Internal protein associated with RNA & polymerase proteins, helical arrangement
PB1/PB2/PA 30-60 Internal proteins associated with RNA transcriptase activity HA 500 Surface glycoprotein trimer responsible for attachment of virus to cells
NA 100 Surface glycoprotein, enzyme activity
NS1 Function unknown
NS2 Function unknown
* occurrence: approximate number of molecules per virus particle It is variation in the HA glycoprotein which is mainly responsible for the recurring outbreaks of influenza and for our inability to control these by immunization [ref 3] . Cleavage of the HA polypeptide into HA1 and HA2 is necessary for the virus particles to be infectious.
The ΝP is one of the type-specific antigens of influenza viruses that distinguishes among the influenza type A, B, and C viruses. The influenza B and C ΝP proteins are larger (560-565 amino acids) than those of type A (498 amino acids) . The ΝP is a multifunctional protein having a structural role in forming the ΝP complex and a role in transcription and replication. The ΝP protein may play a role in determining species specificity. Monoclonal antibodies to the ΝP do not provide passive protection and immunization with this protein induces very limited resistance to infection. However, the ΝP protein is a major antigen recognized by cytotoxic lymphocytes (CTL) and several of the epitopes recognized by the CTL are conserved in human influenza A viruses [ref 4, 5] .
The Ml protein, which is 252 amino acids long, is a virion structural protein that is intimately associated with the lipid bilayer in such a manner that it is in close proximity to both glycoproteins and to the RΝP complex [ref 2, 6] . In a typical influenza A virus, Ml is encoded in an essentially complete transcript of segment 7. It is believed to be a multifunctional protein also having a role in the downregulation of the activity of the virion-associated transcriptase and is located in the nucleus, cytoplasm and plasma membrane in infected cells [ref 7, 8] . Passively transferred monoclonal antibodies to this protein do not confer resistance to infection [ref 9] . Comparison of the sequences of RΝA segment 7 of the H3Ν2 and H1N1 strains show that the sequences coding for the Ml protein of these viruses isolated 38 years apart are highly conserved in keeping with antigenic studies [ref 2] . Comparison of 230 nucleotides of RNA segment 7 from five human H1N1, H2N2 and H3N2 strains isolated over a 43-year period suggests that the same segment 7 was retained throughout the antigenic shifts of HA and NA [ref 10] . Influenza viruses are unique among the respiratory tract viruses in that they undergo significant antigenic variation. Both surface antigens of the influenza A viruses undergo two types of antigenic variation: antigenic drift and antigenic shift. Antigenic drift involves minor antigenic changes in the HA and NA proteins, while antigenic shift involves major antigenic changes in these molecules. Antigenic drift occurs in types A, B, and C virus hemagglutinins but is most pronounced in human influenza A strains. Antigenic drift in the HA occurs by point mutations in the gene, leading to an accumulation of amino acid sequence changes that alter the antigenic sites such that they are no longer recognized by the host's immune system. Antigenic drift also occurs in the NA of influenza viruses and has been correlated with differences in amino acid sequences [ref 11] . The frequency of isolation of NA variants is similar to that for the HA, and sequence analysis shows single amino acid substitutions in the molecule [ref 12] . The humoral immune response in humans is extremely heterogeneous and the limited antibody repertoire against the influenza virus surface antigens in children and young adults probably permits selection of variants with changes in a single epitope [ref 13] .
There is no evidence of persistent or latent infection with influenza viruses . The virus is maintained in humans by direct person-to-person spread during acute infection. Immunologic factors clearly influence the size of an epidemic. Immunity is type-specific .
High rates of hospitalization are observed in children less than 5 years of age (undergoing first infection) and those over 65 years of age. The observation that 14-16% of children seeking medical care for febrile respiratory illness are infected by influenza virus indicates that influenza viruses make a major contribution to outpatient morbidity. Immunity to influenza viruses is incomplete and morbidity following reinfection with the same strain or with a drift strain can occur. Although severe disease can attend reinfection, the morbidity following reinfection is usually less than that following first infection. The economic impact of influenza A virus infection is considerable and morbidity contributes heavily to it. The estimated total cost (direct and indirect costs) of each of three different epidemics varied from 1 to 3 billion dollars depending on the size of the epidemic.
Influenza virus is unique among respiratory viruses in being a cause of excess mortality. Influenza A has caused excess mortality 21 times since 1934. Although morbidity with influenza A virus is concentrated in people less than 20 years of age, the highest rates of excess mortality occur in persons over 65 years of age [ref 14] . Mortality due to influenza is not confined to the bedridden since up to 50% of all deaths occurred in people who were chronically ill but medically stable and functioning independently [ref 15] . The average yearly rate of death due to influenza A virus infection is 1 per 2200 adults 65 years or older [ref 16] .
Prior infection with an influenza virus of one serotype bearing highly related internal antigens such as M and ΝP proteins did not appear to have a major effect on the occurrence or consequences of subsequent infections with influenza viruses belonging to a different subtype. It is reasonable to conclude that immunity to influenza viruses is primary mediated by responses to the surface glycoproteins . Antibody responses to the HA and ΝA are the major effectors of resistance to reinfection or illness following reinfection. Cellular immune factors also contribute to immunity to influenza A virus infection [ref 16] . Class I-restricted ΝP-specific CTL amplified from vaccinia-ΝP recombinant virus-infected animals were capable of a high-level protection following adoptive transfer [ref 17] . In humans, the level of memory class I-restricted CTL present at the time of infection correlated with an enhanced clearance of virus from the respiratory tract [ref 18] . Oligopeptides with amino acid sequences similar to those of the Ν-terminus of the HA2 polypeptide have antiviral activity against influenza A virus in vitro [ref 19] . The oligopeptides probably act by interfering with the function of the N-terminus of the HA2 polypeptide.
Inactivated influenza A and B virus vaccines are licensed for parenteral administration in humans. The vaccines currently in use are designated whole-virus (WV) vaccines or split-product (SP) virus vaccine. The WV vaccines contain intact, formalin- treated virus while the SP vaccines contain purified formalin- treated virus disrupted with chemicals that solubilize the lipid-containing viral envelope. Experimental vaccines contain the isolated HA and NA surface proteins. Satisfactory serological responses were achieved in children and adults with doses of vaccine that caused minimal clinical reactions. Local or systemic allergic reactions occur approximately once in every 3900 vaccinations [ref 20] . Intradermal administration offers no advantage over parenteral administration [ref 21] . Parenteral vaccination with influenza A and B viruses consistently induces resistance to illness and, to a lesser extent, infection with influenza A and B virus [ref 22, 23] . Efficacy ranges from 60 to 80%, the higher value being obtained following challenge with homologous virus. Vaccine is effective in the elderly who are at high risk for morbidity and mortality, but the level of efficacy is often less than seen in young adults [ref 15, 24] . It is suggested that the immunity is of short duration.
Inactivated vaccines stimulate HLA-testricted CTL in adults but their ability to stimulate CTL in unprimed individuals has not been evaluated [ref 25] . In contrast to virus infection, inactivated WV and SP vaccines stimulate a poor CTL response in unprimed mice .
Although influenza A viruses do not differ in mutation rate from other RNA viruses, mutation occurs sufficiently often to provide an ample source for the selection of naturally occurring variants. An important part of the resistance to influenza A virus is mediated by the development of an immune response to HA and NA. These glycoproteins are conserved to a much lesser extent compared to the NP and M proteins. We conceived that newly characterized influenza virus T- cell epitopes of highly conserved proteins may be valuable tools for vaccine development and diagnostic applications . Therefore we focused on the highly conserved influenza M protein. This invention is specifically concerned with the detection of class I binding T cell epitopes of the highly conserved M protein of the influenza virus, which can be recognized by CTL. CTL are of crucial importance in the resistance against virus infections [ref 26, 27] . CTL specific for viruses (or tumors) recognize short viral or tumor protein-derived peptides of about 8-11 amino acids in length, that are presented in the antigen binding groove of major histocompatibility complex (MHC) class I molecules [ref 28, 29] . Recently in several systems vaccination with peptides recognized by antigen specific CTL was shown to prevent lethal virus infection and to delay tumor growth in mice, whereas adoptive transfer of these CTL could induce tumor destruction [ref 30, 31] .
We have succeeded in the identification of influenza virus peptides derived from the highly conserved M protein that bind to the groove of MHC class I molecules, using the antigen processing defective cell line 174.CEM T2 (T2) . This cell line expresses the human MHC class I HLA-A2.1 and HLA-B5 alleles of which only the HLA-A2.1 molecules are expressed as partly empty and unstable molecules that can be stabilized on the cell surface with exogenous addition of binding peptides [ref 32] . If incubation with a peptide results in an increased expression of the HLA-A2.1 on the surface of T2, this implies that the peptide binds to the groove of this MHC class I molecule and is therefore a candidate target antigen for recognition by CTL. In the case of HLA-A2.1, it is known that about 40% of the
Caucasoid population in Western Europe expresses this allele. Using an arbitrary computer scoring system developed by ourselves based on a peptide motif rule developed by others, we screened the amino acid sequences of the influenza M protein [ref 33, 34] . In this scoring system we scored 6 points for an anchor residue, 4 points for a strong residue and 2 points for a weak residue. The score for a given peptide is obtained by multiplication of the scores for each amino acid position. We generated a series of 77 peptides (37 peptides having a length of 9 amino acids, i.e. 9-mers, 24 10-mers, and 16 11-mers) comprising 35 high scoring peptides, 24 low scoring peptides and 18 randomly chosen control peptides. In total 15 peptides of this set were identified to bind to the HLA-A2.1 molecule at a concentration of 100 μg/ml (Table 2) . All HLA-A2.1 binding peptides had a high score using the computer program, none of the low-scoring or control peptides did so (Table 3, 4, 5) . One of the HLA-A2.1 binding peptides of the influenza M protein has previously been described (aa 58-66, Table 2) . An HLA-A2.1 restricted CTL recognizes this defined influenza M epitope [ref 35] .
Summary of the invention
An object of the present invention is therefore to provide synthetic peptides of the influenza M protein for prevention, prophylaxis, therapy and treatment of influenza utilizing these synthetic peptides and pharmaceutical compositions containing the synthetic peptides.
Another object of the invention ist to provide a method of prophylactic or therapeutic treatment of influenza or other Human Influenza Virus-related diseases.
A further object of the present invention is to provide pharmaceutical compositions which can be used for prevention, prophylaxis, therapy and treatment of influenza or other Human Influenza Virus-related diseases . This invention provides a peptide comprising an amino acid sequence derived from a human influenza virus protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex (MHC) Class I molecule.
The present invention also provides specific peptides derived from the amino acid sequence of the human influenza M protein which, because of their capability to bind to HLA molecules, such as e.g. the * HLA-A2.1, HLA-A1, HLA- 3.2, HLA-All.2 or HLA-A24 protein, are candidate peptides to be included in human vaccines that can induce protective or therapeutic T cell responses against human influenza virus . The novel peptides of the present invention are useful in pharmaceutical compositions, as screening tools and in the prevention, prophylaxis, therapy and treatment of influenza or other human influenza virus-induced diseases or other conditions which would benefit from inhibition of influenza virus infection. Preferably, said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.
More specifically, this invention provides a peptide comprising an amino acid sequence derived from human influenza M protein, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:
Peptide Amino acid sequence location in influenza M protein
1 S L L T E V E T Y V (residues 2-11 of M protein)
2 S L L T E V E T Y V L (residues 2-12 of M protein)
3 L L T E V E T Y V (residues 3-11 of M protein)
4 L L T E V E T Y V L (residues 3-12 of M protein)
5 V L M E W L K T R P I (residues 41-51 of M protein) 6 P I L S P L T K G I (residues 50-59 of M protein)
7 I L S P L T K G I (residues 51-59 of M protein)
8 I L S P L T K G I L (residues 51-60 of M protein)
9 G I L G F V F T.L (residues 58-66 of M protein)
10 G I L G F V F T L T V (residues 58-68 of M protein) 11 I L G F V F T L T V (residues 59-68 of M protein)
12 R M G A V T T E V (residues 134-142 of M protein)
13 G L V C A T C E Q I A (residues 145-155 of M protein)
14 Q M V T T T Ν P L (residues 164-172 of M protein)
15 Q M V T T T Ν P L I (residues 164-173 of M protein), and a fragment, homolog, isoform, derivative, genetic variant or conservative variant of any one of said amino acid sequences which has the ability to bind to human MHC Class I allele HLA- A2.1.
This invention further provides a pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to the invention, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. Preferably, said pharmaceutical composition contains a peptide according to the invention which is able to induce a T cell response effective against human influenza virus, in particular a HLA class I- restricted CD8+ cytotoxic T cell response.
In addition, this invention provides a method of prophylactic or therapeutic treatment of influenza or any other human influenza virus-related disease with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a peptide according to the invention, more specifically an immunogenic form of a peptide according to the invention which is able to induce a T cell response effective against human influenza virus, in particular a HLA class I-restricted CD8+ cytotoxic T cell response. The invention provides a peptide as αefined herein for prophylactically or therapeutically inducing in a human individual a HLA class I-restricted CD8+ cytotoxic T cell response effective against human influenza virus .
The invention covers the use of a peptide as defined herein for preparing a pharmaceutical composition for prophylactically or therapeutically inducing in a human individual a HLA class I- restricted CD8+ cytotoxic T cell response effective against human influenza virus .
The invention also provides a process of inducing a human influenza virus-specific cytotoxic T lymphocyte response in a T- lymphocyte culture, comprising the steps of loading antigen- presenting cells which carry empty MHC Class I molecules with a peptide as defined herein, culturing T-lymphocytes in the presence of the peptide-loaded antigen-presenting cells under specific cytotoxic T-lymphocyte response-inducing conditions, and, optionally, isolating a human influenza virus-specific cytotoxic T lymphocyte from the resulting culture and culturing said isolated cytotoxic T-lymphocyte .
The invention provides a human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide as defined herein, and also provides a pharmaceutical composition containing a prophylactically or therapeutically effective amount of a human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide as defined herein, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The invention also provides a method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a human influenza virus-specific cytotoxic T lympho- cyte reactive to a peptide as defined herein.
The invention covers the use of a peptide as defined herein in a diagnostic test or assay to detect human influenza virus- specific T cells or antibodies.
Detailed description of the invention
The invention is directed to peptides comprising an amino acid sequence derived from a human influenza virus protein, in particular the human influenza M protein, wherein said amino acid sequence has the ability to bind to a human MHC class I molecule, preferably a human HLA-A2.1 class I molecule. More specifically, such peptides comprise the following amino acid sequences derived from the noted regions of the human influenza virus (See Table 2; the amino acids are identified by the one- letter code of amino acids) . Table 2: Influenza matrix peptides identified as peptides binding to HLA-A2.1
Peptide Amino acid sequence location in influenza M protein SEQ ID NO
1 S L L T E V E T Y V (residues 2-11 of M protein)
2 S L L T E V E T Y V L (residues 2-12 of M protein)
3 L L T E V E T Y V (residues 3-11 of M protein) 4 L L T E V E T Y V L (residues 3-12 of M protein)
5 V L M E W L K T R P I (residues 41-51 of M protein)
6 P I L S P L T K G I (residues 50-59 of M protein)
7 I L S P L T K G I (residues 51-59 of M protein)
8 I L S P L T K G I L (residues 51-60 of M protein) 9 G I L G F V F T L (residues 58-66 of M protein)
10 GG I L G F V F T L T V (residues 58-68 of M protein) 11 I L G F V F T L T V (residues 59-68 of M protein) 12 R M G A V T T E V (residues 134-142 of M protein) 13 L V C A T C E Q I A (residues 145-155 of M protein) 14 Q _ MM VV TT T'. T N P L (residues 164-172 of M protein) 15 Q M V T T T N P L I (residues 164-173 of M protein)
The data suggest that the peptides mentioned above are single polypeptides of identified sequences. However, homologs, isoforms or genetic variants of these peptides may exist within or outside the cellular environment . This invention encompasses all such homologs, isoforms or genetic variants of the above peptides provided that they bind to the HLA molecule in question.
Polypeptides that are homologs of the peptides specifically include those having amino acid sequences which are at least about 40% conserved in relation to the amino acid sequence set forth in Table 2, preferentially at least about 60% conserved, and more preferentially at least about 75% conserved.
It will be understood by one of ordinary skill in the art that other variants of the peptides shown above are included within the scope of the present invention. This particularly includes any variants that differ from the above mentioned and synthesized peptides only by conservative amino acid substitution. In particular, replacements of C (cysteine) by A (alanine) , S (serine) , α-aminobutyric acid and others are included as it is known that cysteine-containing peptides are susceptible to (air) oxidation during synthesis and handling. Many such conservative amino acid substitutions are set forth as sets by Taylor (1986) . Peptides according to the invention, or fragments thereof, include any variation in the amino acid sequence, whether by conservative amino acid substitution, deletion, or other process, provided that the polypeptides bind to the HLA molecule in question. The fragments of the peptides may be small peptides with sequences of as little as five or more amino acids, said sequences being those disclosed in Table 2 when said polypeptides bind to the HLA-A2.1 molecule.
Polypeptides larger than peptides Νos . 1-15 are especially included within the scope of the present invention when said polypeptides induce a human influenza M protein specific CTL response in appropriate individuals (e.g. HLA-A2.1 positive individuals) and include a (partial) amino acid sequence as set forth in Table 2, or conservative substitutions thereof. Such polypeptides may have a length up to about 30 amino acids, preferably up to about 27 amino acids. Most preferably, however, the peptides have a length of from 9 to 12, more preferably 9 to 11 amino acids.
This invention includes the use of polypeptides Νos. 1-15 generated by every means, whether genetic engineering, peptide synthesis with solid phase techniques or others. The peptides may have various chemical modifications made at the terminal ends and still be within the scope of the present invention. Also other chemical modifications are possible, particularly cyclic and dimeric configurations. The term "derivatives" intends to cover all such modified peptides.
The polypeptides of the present invention find utility for the treatment or prevention of diseases involving the human influenza virus . For all applications the peptides are administered in an immunogenic form. Since the peptides are relatively short, this may necessitate conjugation with a immunogenicity conferring carrier material such as lipids or others or the use of adjuvants .
The magnitude of a prophylactic or therapeutic dose of polypeptides of this invention will, of course, vary with the group of patients (age, sex, weight, etcetera), the nature of the severity or the condition to be treated, the particular polypeptide of this invention and its route of administration. Any suitable route of administration may be employed to achieve an effective dosage of a polypeptide identified by this invention, as well as any dosage form well known in the art of pharmacy. In addition the polypeptides may also be administered by controlled release means and/or other delivery devices, such as, in particular, interferons and T cell activating agents like interleukin-2 etc.
The peptides of this invention may also be useful for other purposes, such as diagnostic use. For example, they may be used to check whether a vaccination with a peptide according to tne present invention has been successful. This may be done in vitro by testing whether the peptide is able to activate T cells of the vaccinated person. They may be used also in diagnostic tests or assays for the detection of human influenza virus- specific antibodies.
The following example illustrates the present invention.
EXAMPLE
In order to identify human influenza M protein peptides that can bind to the groove of HLA-A2.1 molecules, the amino acid sequence of human influenza M protein was examined with an arbitrary computer scoring system developed by ourselves based on a peptide motif rule developed by others [ref 33, 34] . In our scoring system we gave 6 points for an anchor residue, 4 points for a strong residue and 2 points for a weak residue. The score for a given peptide is obtained by multiplication of the scores for each amino acid position.
We generated a set of 77 peptides (37 of them were 9-mers, 24 were 10-mers, and 16 were 11-mers) comprising 35 high scoring peptides, 24 low scoring peptides and 18 randomly chosen control peptides. Peptides having a length of 9, 10 or 11 amino acids were chosen because they fit the presently known rules for the length of peptides that bind to the groove of HLA-A2.1 molecules . Peptides were synthesized by solid phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422) using Fmoc-chemistry. The purity of the peptides was determined by reversed phase HPLC. Peptides were dissolved in DMSO (final DMSO concentration 0.25%) and diluted in 0.9% NaCl to a peptide concentration of 2 mg/ml and stored at -20°C.
To determine which peptides were able to bind to the groove of MHC class I molecules, we used the antigen processing defective cell line 174.CEM T2 (T2) . This cell line expresses the human MHC class I HLA-A2.1 and HLA-B5 alleles of which only the HLA-A2.1 molecules are expressed as partly empty and unstable molecules that can be stabilized on the cell surface with exogenous addition of peptides binding to the peptide presenting groove of these molecules [ref 32] . If incubation with a peptide results in an increased expression of the HLA- A2.1 on the surface of T2, this implies that the peptide binds to the groove of this MHC class I molecule and is therefore a candidate target antigen for recognition by CTL.
The T2 cell line, a gift from Dr. P. Cresswell (Dept . of Immunology, Yale University, New Haven, CT) , was cultured in Iscove's modified Dulbecco's medium (IMDM) (Biochrom KG, Seromed Berlin, Germany) with 2mM glutamine, 100 IU/ml penicillin, 100 μg/ml kanamycin and 10% fetal calf serum (FCS, Hyclone Laboratories Inc. Logan, Utah, USA) . The T2 cells were washed twice in serum free culture medium. 80,000 Cells in 40 μl serum free medium were put into a V bottomed 96 well plate together with 10 μl of the peptide dilution at different concentrations or 10 μl 0.9% NaCl, and incubated overnight at 37°C, 5% C02 in humidified air. The cells were washed once with cold (4°C) "PBA" (0.9% NaCl, 0.5% BSA, 0.02% NaN3) and stained by indirect immunofluorescence . The first antibody BB7.2 (HLA-A2.1 specific monoclonal antibody) was added in a saturating amount and incubated for 30 minutes at 4°C. After two wash steps with cold PBA, FITC-labelled F(ab')2 fragments of goat anti-mouse IgG (Tago Inc Burlinger, CA, USA: 4350) in a dilution of 1:40 was added as the second antibody and incubated for another 30 min at 4°C. The cells were washed once and fluorescence was measured at 488 nanometer on a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) .
The fluorescence Ratio (F.R.) was calculated according to the formula: F.R. = mean fluorescence experimental sample / mean fluorescence background.
Only the 15 peptides described in Table 2 were able, at a concentration of 100 μg/ml, to significantly upregulate the expression of HLA-A2.1 molecules measured as mean HLA-A2.1 fluorescence of T2 cells indicating their binding to the HLA- A2.1 molecule. None of the other human influenza M protein peptides were able to do this. All of the HLA-A2.1 binding peptides had a high score in our scoring system.
These experiments indicate that only a limited proportion of peptides (Nos. 1-15) have the ability to bind to the HLA-A2.1 molecule and are therefore the candidates of the human influenza M protein to be recognized by human CTL because CTL recognize peptides only when bound to the groove of HLA molecules. Furthermore, they are the candidates to be used for either vaccination of human beings in the prevention or therapy of diseases with expression of influenza M protein, or for the in vitro response induction of influenza virus specific CTL.
Our elucidation of peptides derived from the human influenza M protein which bind to human MHC Class I allele HLA- A2.1 allows the formulation of powerful vaccines against human influenza virus-related conditions, such as influenza. Until our invention, only one CTL epitope of the influenza M protein had been elucidated (the immunodominant epitope aa 58-66) .
It is known from studies in mice performed in our group that a peptide representing a subdominant epitope of a tumor cell line can protect mice vaccinated with said peptide against outgrowth of that cell line, although vaccination with tumor cells does not elicit a response against this peptide. We assume that in addition to the immunodominant epitope of the influenza M protein (aa 58-66) the other binding peptides of this protein can have an important immunologic function if used in a vaccine. The 77 peptides synthesized and tested are shown in Table 2 (15 high-scoring and binding influenza matrix peptides) , Table 3 (20 high-scoring but non-binding influenza matrix peptides), Table 4 (24 low-scoring, non-binding influenza matrix peptides) and Table 5 (18 non-binding control influenza matrix peptides) . The result of the binding analyses of the 15 binding peptides is given in Table 6. Binding of peptides is shown as mean fluorescence level of HLA-A2.1 expression in the presence of said peptides divided by the mean fluorescence level of HLA- A2.1 expression without the presence of said peptides. Binding of a peptide is regarded as positive when a value of 1.5 is reached.
Table 3: The non-binding influenza matrix peptides with a high score. The number of the first amino acid is shown. The peptides are ranked according to their computer score .
First aa No. score peptides
14 1152 I I P S G P L K A
14 1152 I I P S G P L K A E I
54 576 P L T K G I L G F V
98 576 K L Y R K L K R E I
106 576 E I T F H G A K E I
50 288 P I L S P L T K G I L 134 288 R M G A V T T E V A
218 288 R I G T H P S S S A
11 144 V L D I I P S G P L
19 144 P L K A E I A Q R L 23 144 E I A Q R L E D V
23 144 E I A Q R L E D V F A
102 144 K L K R E I T F H G A
130 144 L I Y N R M G A V
145 144 G L V C A T C E Q I 172 144 L I R H E N R M V
172 144 L I R H E N R M V L
172 144 L I R H E N R M V L A
191 144 _ Q M A G S S E Q A
228 144 G L K N D L L E N L
Table 4: The Influenza matrix peptides with a low score. The number of the first amino acid is shown. The peptides are ranked according to their computer score.
First aa No. score peptides
13 72 D I I P S G P L K A
42 72 L M E W L K T R P I
42 72 L M E W L K T R P I L 45 72 W L K T R P I L S P L
114 72 E I S L S Y S A G A
114 72 E I S L S Y S A G A L
116 72 S L S Y S A G A L
116 72 S L S Y S A G A L A 123 72 A L A S C M G L I
127 72 C M G L I Y N R M
127 72 C M G L I Y N R M G A
129 72 G L I Y N R M G A
129 72 G L I Y N R M G A V 171 72 P L I R H E N R M
171 72 P L I R H E N R M V
171 72 P L I R H E N R M V L
236 72 N L Q A Y Q K R M
236 72 N L Q A Y Q K R M G V
38 36 D L E V L M E W L
65 36 T L T V P S E R G L
73 36 G L Q R R R F V Q N A
178 36 R M V L A S T A K A 211 36 Q M V Q A M I R I
180 24 V L A S T A K A M Table 5: The Influenza matrix peptides used as a control group The number of the first amino acid is shown. The peptides are ranked according to their seq. no.
First aa No. peptides
20 L K A E I A Q R L
31 V F A G K N T D L
41 V L M E W L K T R 47 K T R P I L S P L
55 L T K G I L G F V
60 L G F V F T L T V
75 Q R R R F V Q N A
88 G D P N N M D K A 91 N N M D K A V K L
95 K A V K L Y R K L
98 K L Y R K L K R E
99 L Y R K L K R E I 107 I T F H G A K E I 173 I R H E N R M V L
179 M V L A S T A K A
194 G S S E Q A A E A
201 E A M E V A S Q A
232 D L L E N L Q A Y
Table 6
No. First score peptides F.R. aa No.
1 2 288 S L L T E V E T Y V 2.38
2 2 288 S L L T E V E T Y V L 3.51
3 3 576 L L T E V E T Y V 2.69
4 3 576 L L T E V E T Y V L 3.11 5 41 1152 V L M E W L K T R P I 2.79
6 50 288 P I L S P L T K G I 1.66
7 51 576 I L S P L T K G I 2.73
8 51 576 I L S P L T K G I L 1.56
9 58 576 G I L G F V F T L 2.92 10 58 576 G I L G F V F T L T V 2.14
11 59 144 I L G F V F T L T V 1.87
12 134 288 R M G A V T T E V 2.12
13 145 144 G L V C A T C E Q I A 1.83
14 164 144 Q M V T T T N P L 3.31 15 164 1 -*. Q M V T T T N P L I 1.98
SEQUENCE LISTING
SEQ ID N0:1
SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 10 amino acids
SerLeuLeuThrGluValGluThrTyrVal 1 5 10
SEQ ID NO:2 SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 11 amino acids
SerLeuLeuThrGluValGluThrTyrValLeu 1 5 10
SEQ ID NO:3
SEQUENCE TYPE : amino acid
SEQUENCE LENGTH: 9 amino acids
LeuLeuThrGluValGluThrTyrVal 1 5
SEQ ID NO:4
SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 10 amino acids
LeuLeuThrGluValGluThrTyrValLeu 1 5 10
SEQ ID NO:5
SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 11 amino acids ValLeuMetGluTrpLeuLysThrArgProIle 1 5 10
SEQ ID NO: 6
SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 10 amino acids
ProIleLeuSerProLeuThrLysGlylle 1 5 10 SEQ ID NO : 7
SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 9 amino acids
IleLeuSerProLeuThrLysGlylle 1 5
SEQ ID NO:8
SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 10 amino acids IleLeuSerProLeuThrLysGlylleLeu 1 5 10
SEQ ID NO: 9
SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 9 amino acids
GlylleLeuGlyPheValPheThrLeu 1 5
SEQ ID NO: 10 SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 11 amino acids
GlylleLeuGlyPheValPheThrLeuThrVal 1 5 10
SEQ ID NO: 11
SEQUENCE TYPE: amino acid
SEQUENCE LENGTH: 10 amino acids
IleLeuGlyPheValPheThrLeuThrVal 1 5 10
SEQ ID NO:12
SEQUENCE TYPE: amino acid -
SEQUENCE LENGTH: 9 amino acids
ArgMetGlyAlaValThrThrGluVal 1 5 SEQ ID Ν0:13
SEQUENCE TYPE : amino acid
SEQUENCE LENGTH: 11 amino acids
GlyLeuValCysAlaThrCysGluGlnlleAla 1 5 10
SEQ ID NO:14
SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 9 amino acids GlnMetValThrThrThrAsnProLeu
SEQ ID NO: 15
SEQUENCE TYPE: amino acid SEQUENCE LENGTH: 10 amino acids
GlnMetValThrThrThrAsnProLeuIle
1 5 10
References
1. Smith W., Andrewes C.H., Laidlaw P.P. A virus obtained from influenza patients. Lancet 1933; i: 66-68.
2. Lamb R.A. The genes and proteins of the influenza viruses. In: Krug RM, ed. The influenza viruses. New York: Plenum, 1989.
3. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu . Rev. Biochem. 1987; 56: 365-394.
4. Bastin J., Rothbard J., Davey J., Jones I., Townsend A. Use of synthetic peptides of influenza nucleoprotein to define epi¬ topes recognized by class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 1987; 165: 1508-1523.
5. Yewdell J.W., Hackett C.J. The specificity and function of T lymphocytes induced by influenza A viruses. In: Krug R, ed. The influenza viruses. New York: Plenum Press, 1989.
6. Joassin L., Vincenzotto C, Cloes J.-M., Bouchet M., Reginster M. Monoclonocal antibodies detect M-protein epitopes on the surface of influenza virions . Arch. Virol. 1987; 95: 183- 195.
7. Biddison W.E., Doherty P.C., Webster R.G. Antibody to influenza virus matrix protein detects a common antigen on the surface of cells infected with type A influenza viruses. J. Exp. Med. 1977; 146: 690-697. ' *
8. Ye Z . , Pal R., Fox J.W., Wagner R.R. Functional and antigenic domains of the matrix (M) protein of influenza virus. J. Virol. 1987; 61: 239-246.
9. Askonas B.A., McMichael A.J., Webster R.G. The immune response to influenza viruses and the problem of protection against infection. In: Beare A.S., ed. Basic and applied influenza research. Boca Raton, FI: CRC Pres, 1982; 159-188.
10. Hall R.M., Air G.M. Variation in nucleotide sequences coding for the N-terminal regions of the matrix and non- structural proteins of influenza A viruses. J. Virol. 1981; 38: 1-7. 11. Colman P.M., Ward C.W. Structure and diversity of influenza virus neuraminidase . Curr. Top. Microbiol . Immunol. 1985; 11: 177-255.
12. Laver W.G., Air G.M., Webster R.G., Markoff L.J. Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase. Virology 1982; 122: 450-460.
13. Wang M.-L., Skehel J.J., Wiley D.C. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J. Virol. 1986; 57: 124-128.
14. Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States . Am. J. Public Health 1986; 76: 761-765.
15. Barker W.H., Mullooly J.P. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244: 2547-2549.
16. Ailing D.W., Blackwelder W.C., Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am. J. Epidemiol. 1981; 113: 30-43.
17. Wraith D.C, Vessey A.E., Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 1987; 68: 433-440.
18. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A.S. Cytotoxic T-cell immunity of influenza. N. Engl . J. Med. 1983; 309: 13-17.
19. Richardson CD., Scheid A., Choppin P.W. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the FI or HA2 viral polypeptides. Virology 1980; 105: 205-222.
20. Davies R., Pepys J. Egg allergy, influenza vaccine, and immunoglobulin E antibody. J. Allergy Clin. Immunol. 1976; 57: 373-383.
21. Nicholson K.G., Tyrrell D.A.J., Harrison P. et al . Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (HINI) vaccine: serological responses and clinical reactions. J. Biol . Stand. 1979; 7: 123-136. 22. Feery B.J., Evered M.G., Morrison E.I. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. J. Infect. Dis . 1979; 139: 237-241.
23. Meiklejohn C, Eickboff T.C, Graves P., Josephine I. Antigenic drift and efficacy of influenza virus vaccines, 1976- 1977. J. Infect. Dis. 1978; 138: 618-624.
24. Strassburg M.A. , Greenland S., Sorviollo F.J., Lieb L.E., Habel L.A. Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness report. Vaccine 1987; 38-44.
25. Ennis F.A., Rook A.H., Hua Q.Y. et al. HLA-restricted virus specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 1981; ii: 887-891.
26. Melief C.J.M. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. in Cancer Res. 1992; 58: 143-175.
27. Kast W.M., Melief C.J.M. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunol. Letters 1991; 30: 229-232.
28. Townsend A., δhlen C, Bastin, Ljunggren H.G., Foster L., Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989; 340: 443-450.
29. Bjorkman P.J., Saper M.A., Samraoui B., Bennet W.S., Strominger J.L., Wiley D.C. Structure df the human class I histocompatibility antigen, HLA-A2 Nature 1987; 329: 506-521.
30. Kast W.M., Offringa R., Peters P.J. et al . Eradication of adenovirus El-induced tumours by ElA-specific cytotoxic T lymphocytes. Cell 1989; 59: 603-614.
31. Schulz M., Zinkernagel R. and Hengartner. Peptide-induced antiviral protection by cytotoxic T cells. PNAS 1991; 88: 991- 993.
32. Salter R.D., Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO 1986; 5: 943-949.
33. Falk K., Rδtzschke 0., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991; 351: 290-296. 34. Hunt D.F., Henderson R.A., Shabanowitz J. et al . Characterization of peptides bound to the class I MHC molecules HLA-A2.1 by mass spectometry. Science 1992; 255: 1261-1263.
35. Morrison J., Elvin J., Latron et al. Identification of the nonamer peptide form influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur. J. Immunol. 1992; 22: 903-907.

Claims

1. A peptide comprising an amino acid sequence derived from a human influenza virus protein, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule .
2. A peptide according to claim 1, wherein said amino acid sequence is derived from human influenza M protein.
3. A peptide according to claim 1 or claim 2, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.
4. A peptide according to claim 1, comprising an amino acid sequence derived from human influenza M protein, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:
Peptide Amino acid sequence location in influenza M protein
1 S L L T E V E T Y V (residues 2-11 of M protein)
2 S L L T E V E T Y V L (residues 2-12 of M protein)
3 L L T E V E T Y V (residues 3-11 of M protein)
4 L L T E V E T Y V L (residues 3-12 of M protein) 5 V L M E W L K T R P I (residues 41-51 of M protein)
6 P I L S P L T K G I (residues 50-59 of M protein)
7 I L S P L T K G I (residues 51-59 of M protein)
8 I L S P L T K G I L (residues 51-60 of M protein)
9 G I L G F V F T L (residues 58-66 of M protein) 10 G I L G F V F T L T V (residues 58-68 of M protein)
11 I L G F V F T L T V (residues 59-68 of M protein)
12 R M G A V T T E V (residues 134-142 of M protein)
13 G L V C A T C E Q I A (residues 145-155 of M protein)
14 Q M V T T T N P L (residues 164-172 of M protein) 15 Q M V T T T N P L I (residues 164-173 of M protein), and a fragment, homolog, isoform, derivative, genetic variant or conservative variant of any one of said amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A2.1.
5. A peptide according to any one of the claims 1-4, having a length of from 9 to 12, preferably 9 to 11 amino acids.
6. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-5, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
7. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-5 which is able to induce a T cell response effective against human influenza virus, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
8. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-5 which is able to induce a HLA class I-restricted CD8+ cytotoxic T cell response effective against human influenza virus, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant .
9. A method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, compris- ing administering to said human individual a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-5.
10. A method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, compris- ing administering to said human individual a prophylactically or therapeutically effective amount of an immunogenic form of a peptide according to any one of the claims 1-5 which is able to induce a T cell response effective against human influenza virus .
11. A method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, compris¬ ing administering to said human individual a prophylactically or therapeutically effective amount of an immunogenic form of a peptide according to any one of the claims 1-5 which is able to induce a HLA class I-restricted CD8+ cytotoxic T cell response effective against human influenza virus.
12. A peptide according to any one of claims 1-5 for prophylactically or therapeutically inducing in a human individual a HLA class I-restricted CD8+ cytotoxic T cell response effective against human influenza virus.
13. Use of a peptide according to any one of claims 1-5 for preparing a pharmaceutical composition for prophylactically or therapeutically inducing in a human individual a HLA class I- restricted CD8+ cytotoxic T cell response effective against human influenza virus .
14. A process of inducing a human influenza virus-specific cytotoxic T lymphocyte response in a T-lymphocyte culture, comprising the steps of loading antigen-presenting cells which carry empty MHC Class I molecules with a peptide according to any one of the claims 1-5, culturing T-lymphocytes in the presence of the peptide-loaded antigen-presenting cells under specific cytotoxic T-lymphocyte response-inducing conditions, and, optionally, isolating a human influenza virus-specific cytotoxic T lymphocyte from the resulting culture and culturing said isolated cytotoxic T-lymphocyte.
15. A human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide according to any one of the claims 1-5.
16. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a human influenza virus- specific cytotoxic T lymphocyte reactive to a peptide according to any one of the claims 1-5, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
17. A method of prophylactic or therapeutic treatment of a human influenza virus-related disease with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a human influenza virus-specific cytotoxic T lymphocyte reactive to a peptide according to any one of the claims 1-5.
18. Use of a peptide according to any one of claims 1-5 in a diagnostic test or assay to detect human influenza virus-specific T cells or antibodies.
PCT/NL1994/000114 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-i molecule WO1994026903A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68585/94A AU6858594A (en) 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-t molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93201429.3 1993-05-18
EP93201429 1993-05-18

Publications (2)

Publication Number Publication Date
WO1994026903A2 true WO1994026903A2 (en) 1994-11-24
WO1994026903A3 WO1994026903A3 (en) 1995-06-01

Family

ID=8213836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1994/000114 WO1994026903A2 (en) 1993-05-18 1994-05-18 Human influenza virus peptides binding hla-i molecule

Country Status (4)

Country Link
AU (1) AU6858594A (en)
IL (1) IL109664A0 (en)
WO (1) WO1994026903A2 (en)
ZA (1) ZA943438B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703783A1 (en) * 1993-03-05 1996-04-03 Cytel Corporation Hla-a2.1 binding peptides and their uses
EP0726941A1 (en) * 1993-08-06 1996-08-21 Cytel Corporation METHODS FOR $i(EX VIVO) THERAPY USING PEPTIDE-LOADED ANTIGEN PRESENTING CELLS FOR THE ACTIVATION OF CTL
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
US6448071B1 (en) 1996-03-28 2002-09-10 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
EP1843158A1 (en) * 2006-04-05 2007-10-10 Micronas Holding GmbH Pathogen detection system
WO2009109428A2 (en) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
US7914797B2 (en) 2005-12-06 2011-03-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Influenza vaccine
US8642531B2 (en) 2004-04-13 2014-02-04 Immune Targeting Systems Ltd. Influenza antigen delivery vectors and constructs
US8759281B2 (en) 2004-04-13 2014-06-24 Immune Targeting Systems Ltd. Antigen delivery vectors and constructs
US9446116B2 (en) 2006-02-07 2016-09-20 Peptcell Limited Peptide sequences and compositions
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008852A1 (en) * 1987-05-14 1988-11-17 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008852A1 (en) * 1987-05-14 1988-11-17 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY, vol.22, no.4, 1992, WEINHEIM, BRD pages 903 - 907 MORRISON, J. ET AL. 'Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes' cited in the application *
EUROPEAN JOURNAL OF IMMUNOLOGY, vol.23, no.6, June 1993 pages 1215 - 1219 NIJMAN H. W. ET AL. 'Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes' *
HUMAN IMMUNOLOGY, vol.37, no.4, August 1993 pages 252 - 258 SAUMA, S.Y. ET AL. 'Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the Influenza A virus Matrix Protein' *
NATURE., vol.351, 23 May 1991, LONDON GB pages 290 - 296 FALK, K. ET AL. 'Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules' cited in the application *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703783A4 (en) * 1993-03-05 1999-03-10 Cytel Corp Hla-a2.1 binding peptides and their uses
EP0703783A1 (en) * 1993-03-05 1996-04-03 Cytel Corporation Hla-a2.1 binding peptides and their uses
EP0726941A1 (en) * 1993-08-06 1996-08-21 Cytel Corporation METHODS FOR $i(EX VIVO) THERAPY USING PEPTIDE-LOADED ANTIGEN PRESENTING CELLS FOR THE ACTIVATION OF CTL
EP0726941A4 (en) * 1993-08-06 1999-06-16 Cytel Corp METHODS FOR -i(EX VIVO) THERAPY USING PEPTIDE-LOADED ANTIGEN PRESENTING CELLS FOR THE ACTIVATION OF CTL
US6448071B1 (en) 1996-03-28 2002-09-10 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6734013B2 (en) 1997-03-28 2004-05-11 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999013095A3 (en) * 1997-09-11 1999-06-10 Univ Johns Hopkins Med Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
US8759281B2 (en) 2004-04-13 2014-06-24 Immune Targeting Systems Ltd. Antigen delivery vectors and constructs
US8642531B2 (en) 2004-04-13 2014-02-04 Immune Targeting Systems Ltd. Influenza antigen delivery vectors and constructs
US11066353B2 (en) 2004-04-13 2021-07-20 Altimmune Uk Ltd Antigen delivery vectors and constructs
US7914797B2 (en) 2005-12-06 2011-03-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Influenza vaccine
US10335480B2 (en) 2006-02-07 2019-07-02 Peptcell Limited Peptide sequences and compositions
US10765734B2 (en) 2006-02-07 2020-09-08 Peptcell Limited Influenza peptides and compositions
US11439702B2 (en) 2006-02-07 2022-09-13 Peptcell Limited Influenza peptides and compositions
US10279032B2 (en) 2006-02-07 2019-05-07 Peptcell Limited Peptide sequences and compositions
US9889191B2 (en) 2006-02-07 2018-02-13 Peptcell Limited Peptide sequences and compositions
US9446116B2 (en) 2006-02-07 2016-09-20 Peptcell Limited Peptide sequences and compositions
EP1843158A1 (en) * 2006-04-05 2007-10-10 Micronas Holding GmbH Pathogen detection system
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US9446143B2 (en) 2007-08-31 2016-09-20 Altimmune Uk Limited Influenza antigen delivery vectors and constructs
US10155049B2 (en) 2007-08-31 2018-12-18 Altimmune UK, LTD Influenza antigen delivery vectors and constructs
RU2540871C2 (en) * 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Self-assembling peptide nanoparticles effective as vaccines
US8546337B2 (en) 2008-02-01 2013-10-01 Alpha-O-Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP2011511773A (en) * 2008-02-01 2011-04-14 アルファ−オー・ペプチドズ・アーゲー Self-assembling peptide nanoparticles useful as vaccines
WO2009109428A3 (en) * 2008-02-01 2010-04-01 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
WO2009109428A2 (en) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines

Also Published As

Publication number Publication date
ZA943438B (en) 1995-01-20
IL109664A0 (en) 1994-08-26
AU6858594A (en) 1994-12-12
WO1994026903A3 (en) 1995-06-01

Similar Documents

Publication Publication Date Title
US11439702B2 (en) Influenza peptides and compositions
EP2023952B1 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
KR102625645B1 (en) Vaccines against hepatitis B virus
Kuwano et al. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response.
WO1994026903A2 (en) Human influenza virus peptides binding hla-i molecule
Kuwano et al. Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytes.
Schadeck et al. CTL epitopes identified with a defective recombinant adenovirus expressing measles virus nucleoprotein and evaluation of their protective capacity in mice
AU2013201008B2 (en) Peptide sequences and compositions
Kuwano Let us know how access to this document benefits you.
ENNIS Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA